Personalized neoantigen vaccine shows no cancer recurrence in small phase 1 kidney cancer trial

Evidence stage: Early HumanRegulatory status: InvestigationalGuideline status: Not addressed

A personalized cancer vaccine (PCV), built to target each patient’s own tumor-specific mutations (neoantigens) and given with or without the immunotherapy drug ipilimumab, produced no recurrence in any of 9 patients with high-risk, fully resected clear cell renal cell carcinoma (kidney cancer) at a median follow-up of about 40 months after surgery, in a phase 1, first-in-human trial (ClinicalTrials.gov NCT02950766; primary publication in Nature, DOI 10.1038/s41586-024-08507-5) led by researchers at Yale School of Medicine and the Dana-Farber Cancer Institute. All 9 participants developed T-cell immune responses against the vaccine’s target mutations, including against known kidney-cancer driver-gene mutations (in genes called VHL, PBRM1, BAP1, KDM5C, and PIK3CA), and no dose-limiting toxicities were reported. This is an early-phase, adjuvant (post-surgery, no visible cancer remaining) safety and immunogenicity trial in a very small number of patients, not a treatment for active/measurable kidney cancer and not yet compared against standard follow-up care in a randomized trial.

What This Means

In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9 patients developed T-cell immune responses against the vaccine targets, and none had a cancer recurrence at a median follow-up of about 40 months — a real, favorable early signal in a population that otherwise faces a meaningful risk of recurrence after surgery alone.

What This Doesn't Mean

This is a 9-patient, single-arm, phase 1 safety and immunogenicity trial with no randomized control group — it does NOT prove the vaccine caused the lack of recurrence, since some of these patients might not have recurred without it. No FDA approval exists for this vaccine, and it is not an available or standard treatment. A larger, randomized trial would be needed to establish whether this vaccine actually reduces recurrence risk compared with surveillance alone.

Why It Matters

A favorable safety profile and a real, measurable immune response against a patient's own tumor-specific mutations in every single participant is a genuine, if early, proof-of-concept for personalized cancer vaccines in kidney cancer — a cancer type with very few adjuvant (post-surgery, preventive) treatment options.

Promise & Proof

Proof — strength of the evidence 2 / 5
  • Base score from evidence stage: Early Human.
Promise — potential significance if later evidence holds up 4 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.
  • An early-stage finding (preclinical or early human) that already shows at least one concrete signal of significance above.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with high-risk, fully surgically resected clear cell renal cell carcinoma (stage III or IV, no remaining visible cancer after surgery), given a personalized neoantigen vaccine with or without ipilimumab in the adjuvant (post-surgery, preventive) setting, in a phase 1, first-in-human trial. (Adults)

This is not an available treatment; it is early-phase investigational research restricted to a small number of trial participants at a small number of academic centers. No dose-limiting toxicities were reported, but this record has not independently reviewed the trial's full adverse-event data, which should be added before publication.

Full evidence details
Study design
Non-randomized trial
Sample size
9

Funding & Conflicts

Reported academic/institutional sponsorship (Dana-Farber Cancer Institute and Yale School of Medicine investigators) — not independently confirmed against a primary corporate- or grant-disclosure document.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

Personalized neoantigen vaccine shows no cancer recurrence in small phase 1 kidney cancer trial

https://cancerdiscoveries.com/discoveries/personalized-neoantigen-vaccine-shows-no-cancer-recurrence-in-small-phase-1-kidney-cancer-trial/

Evidence stage: Early Human

What This Means

In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9 patients developed T-cell immune responses against the vaccine targets, and none had a cancer recurrence at a median follow-up of about 40 months — a real, favorable early signal in a population that otherwise faces a meaningful risk of recurrence after surgery alone.

What This Doesn't Mean

This is a 9-patient, single-arm, phase 1 safety and immunogenicity trial with no randomized control group — it does NOT prove the vaccine caused the lack of recurrence, since some of these patients might not have recurred without it. No FDA approval exists for this vaccine, and it is not an available or standard treatment. A larger, randomized trial would be needed to establish whether this vaccine actually reduces recurrence risk compared with surveillance alone.

Why It Matters

A favorable safety profile and a real, measurable immune response against a patient's own tumor-specific mutations in every single participant is a genuine, if early, proof-of-concept for personalized cancer vaccines in kidney cancer — a cancer type with very few adjuvant (post-surgery, preventive) treatment options.

Primary sources

  • NeoVax Plus Ipilimumab in Renal Cell Carcinoma trial registry — https://clinicaltrials.gov/study/NCT02950766 (NCT02950766)

Date verified: 2026-08-13

Correction status: No correction or retraction